The drugs behind the weight-loss boom may also be reducing the risk of heart attack and stroke. A new analysis finds that people taking GLP-1 medications were less likely to experience heart attacks, strokes, or die early compared with those given a placebo, with benefits lasting over several years.
Published in Cardiovascular Diabetology – Endocrinology Reports, the study pooled data from more than 90,000 patients across 11 clinical trials and found about a 13 percent reduction in major cardiovascular events over nearly three years.
“This is the most comprehensive review to date of long‑term cardiovascular outcome trials for GLP‑1 receptor agonists,” lead author Simon Cork said in a press release. “When taken over a prolonged period of at least one year, these medications do much more than help control blood sugar or weight.”
GLP-1 Drugs and Heart Health in High-Risk Patients
The analysis focused on adults already at elevated risk of cardiovascular disease, including people with type 2 diabetes, obesity, or existing heart conditions.
Researchers combined results from large, randomized, placebo-controlled trials designed to track long-term heart outcomes in these groups. Across the studies, patients taking GLP-1 drugs had lower rates of cardiovascular death, non-fatal heart attack, and non-fatal stroke, along with fewer hospitalizations for heart failure.
The risk reduction was consistent across different drugs and study designs, showing this isn’t limited to a single medication. Researchers saw similar reductions when they looked at heart attack and stroke on their own.
Read More: Ozempic and Other GLP-1 Side Effects May Outweigh the Benefits
How GLP-1 Drugs May Improve Heart Health
GLP-1 receptor agonists were originally designed to lower blood sugar. But their heart benefits likely come from a combination of effects.
The drugs can reduce body weight, lower blood pressure, and improve blood sugar control, all of which are closely linked to cardiovascular risk. These changes alone can lower strain on the heart and reduce the likelihood of long-term damage.
At the same time, evidence shows the drugs may act directly on the cardiovascular system. GLP-1 receptors are found in heart tissue and blood vessels, and the drugs appear to improve blood vessel function, reduce inflammation, and influence the buildup of plaque in arteries.
Safety, Side Effects, and What Comes Next
The analysis also examined safety across the trials. It found no meaningful increase in serious risks such as severe hypoglycemia or acute pancreatitis, with overall rates of pancreatitis remaining low and similar to placebo.
Gastrointestinal side effects were more common. Symptoms like nausea, vomiting, and diarrhea occurred more frequently in people taking GLP-1 drugs, with some studies reporting rates up to 17 percent higher than placebo. While typically manageable, these effects can affect how well patients tolerate the drugs over time.
Because the analysis combined results from multiple trials rather than individual patient data, it cannot fully capture how outcomes vary between individuals. Differences in dosing and patient characteristics may also play a role.
Even so, the findings were consistent across large studies. Cardiovascular disease remains the leading cause of death worldwide, and even modest reductions in risk can translate into a large number of prevented events.
“These drugs have the potential to become a key part of healthcare strategies, especially for people with type 2 diabetes or established heart disease. Using them earlier and more widely across populations could help prevent thousands of serious cardiovascular events,” Cork concluded in the press release.
This article is not offering medical advice and should be used for informational purposes only.
Read More: 8 Ways to Boost the Effects of Ozempic and Other GLP-1 Drug Treatments
Article Sources
Our writers at Discovermagazine.com use peer-reviewed studies and high-quality sources for our articles, and our editors review for scientific accuracy and editorial standards. Review the sources used below for this article:
